Pradeep Bhadauria

Mr. Pradeep Bhadauria is the CEO of Aspergen Inc. (a Cipla – Kemwell Biopharma joint venture).

With a Masters’ degree in Pharmacy from Birla Institute of Technology, Mr. Bhadauria has a successful track record of developing and filing numerous products, including many first-to-file and first-to-market opportunities. He has worked on multiple dosage forms, and has extensive experience in working on complex generics, 505(B)2, specialty and other difficult-to-formulate products. He also holds several patents and has published research in various publications. With over two decades of experience, Mr. Bhadauria is an industry veteran with expertise in the area of Pharmaceutical Research and Development.

Mr. Bhadauria joined Cipla in 2020 & prior to which he served as CSO and member of the Executive Committee at Amneal Pharmaceutical Inc. He has also held leadership positions in Apotex, Allergan/Actavis, Watson Pharmaceuticals, Sandoz, and Ranbaxy.

As the CSO and member of Management council at Cipla, Mr. Bhadauria leads the Global Integrated Product Development (IPD) division to strengthen the company’s position as an innovation led generic and specialty pharmaceutical organization.